You can accelerate drug development in TK2d

(thymidine kinase type 2 deficiency)

Your experience with TK2d is important and can help researchers advance treatments for your community.

By joining RDMD, you can contribute your de-identified medical records to multiple research efforts for TK2d without leaving home. We do the work to collect your information, and you’ll receive all your records in your secure account, at no cost.

Questions? Check out our FAQ
Join the TK2d program in 10 minutes

Help this community hit the research goal by sharing with your network!
Mens Health Magazine
Mens Health Magazine
RDMD Research for TK2d is approved and monitored by an independent ethics review board called WIRB (Western Institutional Review Board). WIRB is a group of people who review research studies to protect the rights and welfare of human subjects. They provide in-depth regulatory expertise to support development of research protocols and documentation.Read more.

Why join the TK2d program?

Key benefits for you:

Reduce the time for thymidine kinase type 2 deficiency drug development

All your medical data in one place

Follow new clinical trials

Make your de-identified health information part of multiple research projects

Your dashboard
Your dashboard

Our work with TK2d research

Inside each of our cells are mitochondria, or the powerhouses of the cell. Their job is to make the energy the body needs to function properly, including actions like lifting your arms or inflating your lungs with each breath. This energy is referred to as adenosine triphosphate, or ATP. To make ATP, mitochondria need enzymes, a type of protein. When there is an error, or mutation in the DNA that code for the enzyme or protein, the mutation can cause a mitochondrial disease. One type of mitochondrial disease is thymidine kinase 2 deficiency, or TK2d. TK2d is a very rare inherited genetic disease that results in an enzyme deficiency that affects mitochondrial DNA (mtDNA). With TK2d, less mtDNA is being made, which means muscles don’t have enough energy and cannot function right. Symptoms of TK2d include muscle weakness (myopathy), difficulty breathing, droopy or saggy eyelids, trouble chewing and swallowing or fatigue. TK2d can present in infants, children or adults.

  • Jumpstart
  • Accelerate
  • Insights

The TK2d program is in the jumpstart stage.

Be part of research

How it works

Sign up

1. Sign up

Create your private account and review our research consent (takes about 10 minutes)

We get to work

2. We get to work

We do all the behind-the-scenes work to retrieve and process your records

Empower research

3. Empower research

Track your contribution to research projects and, based on your records, find out if you qualify for new clinical trials based on your records

Be part of research

Questions? Check out our FAQ

Our values & principles.

Patients own their data

We believe that the only way to keep data accessible to the researchers who need it is by enabling patients to own and control their own data. Patients decide for themselves whether they want to privately and securely contribute to research, rather than having the decision made on their behalf.

We protect patient privacy

We abide by a strict research consent and privacy policy. We only share de-identified data with researchers, foundations, and therapeutic companies with patients’ consent. Protecting the privacy of patients and ensuring the security of their information is our highest priority.

Researchers gain access

We aim to make useful data accessible to all researchers who have legitimate research questions or research programs. For academic research, we offer access without charge. We take research ethics seriously, and we have policies in place to ensure that research is conducted with integrity.

Inclusiveness in the community

We don’t like to take sides—we give all members of the community the option to get involved. Success in rare disease research takes a village and we always welcome additional collaborators who can advance and benefit from the mission.

Driving forward therapeutic development

Our primary mission is to accelerate drug development, so we prioritize generating insights specifically relevant to therapeutic research. We invest deeply in quality, security, and compliance to make this a reality.